Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved. A few retrospective analyses and a small sample of prospective studies have found that neoadjuvant therapy with imatinib mesylate can improve R0 resection rates. Whether neoadjuvant therapy prolongs long-term survival remains unclear. The primary objective of this study was to evaluate 5-year progression-free survival (PFS) for GIST patients with high recurrence risk after neoadjuvant treatment with imatinib mesylate.

NCT Number	NCT04933669
Lead Sponsor	First Affiliated Hospital of Zhejiang University Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Ningbo No. 1 Hospital
Conditions	Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant
Enrollment	122 participants
Start Date	2021-09-07
Primary Completion	2029-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2021-10-12